Stock Evaluator: Palomino Laboratories Inc. (PALX)
Palomino Laboratories Inc. PALX
$14.00
-2.42
-14.74%
September 2, 2026 1:42:28 PM
EST
Volume: 911
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Information Technology | Semiconductors & Semiconductor Equipment |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Palomino Laboratories Inc. designs and manufactures MicroLED-based optical devices. It offers compound semiconductor solutions that enable the next generation of AI, data communication systems, and other applications.Palomino Laboratories Inc. was formerly known as Unite Acquisition 3 Corp. and changed its name to Palomino Laboratories Inc. in September 2025. The company was incorporated in 2022 and is based in Goleta, California.
Financial Summary
| Share Statistics | PALX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $453.8 | $4,575.5 | 36% |
|
| Shares Out (Mil) | 21.8 | 62.3 | 32% |
|
| Institutional Ownership | na | 94.7% | na |
|
| Float (Mil) | na | 81.6 | na |
|
| Beta | na | 1.65 | na |
|
| Avg Daily Volume (000s) | 3 | 878 | 12% |
|
| Price Change (52-week) |
na | 57.8% | na |
|
| Growth | PALX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 8.5% | na |
|
| Net Income (5yr) | na | (4.4%) | na |
|
| EPS (5yr) | na | 4.3% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (7.4%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PALX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $924 | na |
|
| Net Income (TTM) (Mil) | ($5) | $29 | 33% |
|
| EPS (TTM) | ($0.332) | $0.400 | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | $140 | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $48 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $91 | 10% |
|
| Enterprise Value (Q1) (Mil) | na | $4,986 | na |
|
| Valuation | PALX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 18.45 | 4.48 | 95% |
|
| P/E | na | 46.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 2.4 | na |
|
| Ratios | PALX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 45.6% | na |
|
| Net Margin | na | 7.6% | na |
|
| ROA | (45.4%) | 3.5% | 12% |
|
| ROE | (51.5%) | 6.2% | 15% |
|
| Liabilities to Assets | 2.3% | 31.1% | 1% |
|
| F-Score | 2 | 5 | 7% |
|
Palomino Laboratories Inc. did not pass any screens on 9/1/2026.
